Vogenx to Present New Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2023 Annual Conference
May 30, 2023
DURHAM, NC. — Vogenx, Inc., an emerging, clinical-stage biopharmaceutical company developing novel, therapeutics to address unmet needs in metabolic disease, today announced that it will present new phase 2 clinical data (NCT05541939) at the Endocrine Society (ENDO) 2023 Annual Conference on its candidate, Mizagliflozin, an SGLT1 inhibitor. Vogenx will present the data during an in-person poster session. ENDO 2023 will take place June 15-18, 2023 in Chicago, Illinois.
The poster presentation details are summarized below:
ENDO 2023 In-Person Poster Presentation
- Title: Inhibition Of Intestinal SGLT1 With Mizagliflozin For The Treatment Of Post-bariatric Hypoglycemia
- Poster Number: FRI-605
- Date & Time: June 16, 2023; 12:00 PM
- Session Number: PA6
- Presenting Author: Helen Margaret Lawler, MD, of the University of Colorado School of Medicine
To learn more about Vogenx and its leadership team, visit the website at www.vogenx.com.
About Vogenx, Inc.
Vogenx, Inc. is a clinical-stage life science company based in Durham, North Carolina. The Company is focused on the development of novel treatments for metabolic diseases with unmet medical need. For more information, please visit www.vogenx.com.
For more information:
+1 919.659.5677